Drug Master Files, manufacturer listings, and Electronic Common Technical Document (eCTD) submissions are foundational to regulatory compliance. Yet even experienced regulatory, quality, and operations...
The global Unique Device Identification (UDI) landscape is entering a critical enforcement phase — and 2026 will be a challenging year for medical device manufacturers operating in the European Union...
The FDA’s final rule, “Revising the National Drug Code Format and Drug Label Barcode Requirements,” establishes a uniform 12-digit format for FDA-assigned National Drug Codes (NDCs) ...
UDI product data is now due for specific scenarios (enforced as of December 8, 2022). Class I and Unclassified medical devices that are required to be labeled with a UDI code must submit product data...
LexisNexis Life Sciences Solutions and ONIX expand strategic alliance to guide pharma customers to market faster Professionals in the life sciences industry rely on unique regulatory affairs expertise...
The FDA’s final rule, “Revising the National Drug Code Format and Drug Label Barcode Requirements,” establishes a uniform 12-digit format for FDA-assigned National Drug Codes (NDCs). This change will standardize how drugs marketed in the U.S. are identified and requires action across the pharmaceutical supply chain.
Currently, FDA assigns 10-digit NDCs in multiple formats. Beginning March 7, 2033, FDA will:
This applies to human drugs (including biologics) and animal drugs. The rule affects only FDA-assigned NDCs and doesnot change formats used for other purposes, such as the HIPAA 11-digit reimbursement standard.
FDA will continue assigning 10-digit NDCs during this time. Stakeholders should use this window to:
Companies have three years to update labeling and deplete old stock. During this period, FDA does not intend to object to continued use of 10-digit NDCs on labels.
After March 7, 2036, drugs introduced into interstate commerce with 10-digit NDCs may be subject to regulatory action.
Organizations—including manufacturers, distributors, pharmacies, payors, and healthcare providers—should ensure systems can handle both 10- and 12-digit NDCs during the transition period.
The rule also aligns with DSCSA requirements:
This presents an opportunity to streamline labeling and serialization processes.
FDA will automatically convert drug listing files to the 12-digit format on the effective date. No new submission is required solely due to the format change, though listings should reflect updated labeling once revised.
While 2033 may seem far away, updating labeling, enterprise systems, serialization processes, and supply chain integrations will take time. Early planning will reduce compliance risk and prevent last-minute disruptions.
Connect with our team to assess your readiness and build a compliant, future-proof strategy well ahead of the deadline.
Contact us